<DOC>
	<DOCNO>NCT00257530</DOCNO>
	<brief_summary>This study test whether addition imiquimod standard antimony therapy provide significant benefit subject newly diagnose cutaneous leishmaniasis . Based previous result , hypothesize lesion patient receive combine treatment pentavalent antimony imiquimod first line therapy resolve rapidly produce less scar treatment pentavalent antimony alone .</brief_summary>
	<brief_title>Imiquimod Plus Antimony Immunochemotherapy Cutaneous Leishmaniasis</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Males/Females 5 65 yr CL diagnosis confirm &gt; 4 week time disease prior antileishmanial therapy CL negative pregnancy test inform write consent parent consent &lt; 18yrs patient &gt; 25cm2 lesion ( ) &gt; 6 cutaneous lesion mucosal lesion previous exposure Imiquimod antileish treatment participation another protocol within 30 day prior study acute chronic illness / medication may interfere significant psychiatric illness anaphylaxis severe allergic reaction propose drug patient unlikely cooperate concomitant infection pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>